a
Table S-6: P53 mutations detected in plasma of cancer patients with non-metastatic disease
Total # patients # patients % mutations
Exons patients with tumor with plasma (plasma/
Cancer Type Stage tested tested mutation mutation tumor) Detection Method Comments Reference
colorectal cancer B+C 5-8 33 10 7b 70% b mismatch ligation mutation tested in serum, not Hibi et al., 1998
B 7 5 71% assay plasma
C 3 2 67%
large bowel B+C 5-8 17 3 2 67% SSCP 1 each stage B, C (both ms) Mayall et al., 1998
carcinoma B 1 1 100% band excision, elution, 0/20 plasma DNA from healthy
C 2 1 50% reamplification controls tested positive
colorectal cancer A-C 4-8 104 31 d 9b 29% b SSCP Mutations found in serum of CRC Wang et al., 2004
A 2 0 0% + sequencing patients. No mutation in serum DNA
B 15 3 20% from 50 healthy controls
C 14 6 43%
colorectal cancer I-III 5-8 66 19 e 7 37% SSCP, sequencing of 20 tumors with mutation, but 1 Bazan et al., 2006
I 4 2 50% altered bands corresponding plasma sample did
II 8 3 38% not amplify.
III 7 2 29%
lung (NSCLC) I-III 5-8 64 26 19 73% tumors: 22 ms, 4 fs, 1 ns (2 Andriani et al., 2004
Clone PCR pdt, plaque
different muts in 1 tumor)
hybridization assay Note: Mut frequency in plasma
(Sensitivity 1/103 to 1/104). very low (<1%) by direct seq.
MASA or restriction digest.
lung (small cell) I-III - LD 5-8 35 6d 5 83% SSCP, sequencing of Patients w microsat alt and p53 mut Gonzalez et al., 2000
(limited altered bands in plasma had better survival than
disease) those with no or 1 mutation.
ovarian cancer I-III 5-8 27 12 2 17% SSCP (sequencing of Otsuka et al., 2004
I 4 0 0% shifted bands in tumor,
II 1 0 0% not plasma)
III 7 2 29%
ovarian cancer I-III 2-11 137 60 d 17 c 28% c Swisher et al., 2005
I 3 1 33% PCR and/or sequencing,
II 2 0 0% ligase detction rxn.
III 55 16 29%
a
The literature was reviewed for English language publications that provided the following information: (1) tumor stage: only non-metastatic tumors, Stages I-III, were included (for
colorectal cancer, modified Dukes Stages A-C); (2) the number of tumor samples with identified p53 mutations; (3) the number of corresponding plasma DNA samples that were
positive for the same personalized p53 mutation detected in the tumor. The literature review included publications cited within Fleischhacker and Schmidt (2007).
b
Mutations were detected in serum, rather than plasma.
c
Mutations were detected in serum and/or plasma.
d
The number of tumors with p53 mutations was given, but the specific mutations were not listed.
e
Specific p53 mutations were listed in some cases; in other cases, only the exon in which the mutation was located was given.
1